{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T22:09:24Z","timestamp":1785881364583,"version":"3.56.0"},"reference-count":36,"publisher":"Georg Thieme Verlag KG","issue":"04","funder":[{"name":"M.M. is a British Heart Foundation (BHF) Chair Holder","award":["(CH\/16\/3\/32406)"],"award-info":[{"award-number":["(CH\/16\/3\/32406)"]}]},{"name":"BHF program grant support","award":["(RG\/16\/14\/32397"],"award-info":[{"award-number":["(RG\/16\/14\/32397"]}]},{"name":"M.M. is also supported by the Leducq Foundation","award":["18CVD02"],"award-info":[{"award-number":["18CVD02"]}]},{"name":"Research Center on Vascular\n                        Ageing and Stroke","award":["868624"],"award-info":[{"award-number":["868624"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Horm Metab Res"],"published-print":{"date-parts":[[2022,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Lipoprotein apheresis (LA) is currently the most powerful intervention possible\n                    to reach a maximal reduction of lipids in patients with familial\n                    hypercholesterolemia and lipoprotein(a) hyperlipidemia. Although LA is an\n                    invasive method, it has few side effects and the best results in preventing\n                    further major cardiovascular events. It has been suggested that the highly\n                    significant reduction of cardiovascular complications in patients with severe\n                    lipid disorders achieved by LA is mediated not only by the potent reduction of\n                    lipid levels but also by the removal of other proinflammatory and proatherogenic\n                    factors. Here we performed a comprehensive proteomic analysis of patients on LA\n                    treatment using intra-individually a set of differently sized apheresis filters\n                    with the INUSpheresis system. This study revealed that proteomic analysis\n                    correlates well with routine clinical chemistry in these patients. The method is\n                    eminently suited to discover new biomarkers and risk factors for cardiovascular\n                    disease in these patients. Different filters achieve reduction and removal of\n                    proatherogenic proteins in different quantities. This includes not only\n                    apolipoproteins, C-reactive protein, fibrinogen, and plasminogen but also\n                    proteins like complement factor B (CFAB), protein AMBP, afamin, and the low\n                    affinity immunoglobulin gamma Fc region receptor III-A (Fc\u03b3RIIIa) among\n                    others that have been described as atherosclerosis and metabolic vascular\n                    diseases promoting factors. We therefore conclude that future trials should be\n                    designed to develop an individualized therapy approach for patients on LA based\n                    on their metabolic and vascular risk profile. Furthermore, the power of such\n                    cascade filter treatment protocols may improve the prevention of cardiometabolic\n                    disease and its complications.<\/jats:p>","DOI":"10.1055\/a-1776-7943","type":"journal-article","created":{"date-parts":[[2022,4,12]],"date-time":"2022-04-12T22:48:01Z","timestamp":1649803681000},"page":"238-249","source":"Crossref","is-referenced-by-count":11,"title":["Precision Medicine Approach for Cardiometabolic Risk Factors in\n                    Therapeutic Apheresis"],"prefix":"10.1055","volume":"54","author":[{"given":"X.","family":"Yin","sequence":"additional","affiliation":[{"name":"Kings College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Takov","sequence":"additional","affiliation":[{"name":"Kings College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Straube","sequence":"additional","affiliation":[{"name":"Zentrum f\u00fcr Apherese- und H\u00e4mofiltration am INUS\n                    Tagesklinikum, Cham, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Voit-Bak","sequence":"additional","affiliation":[{"name":"Zentrum f\u00fcr Apherese- und H\u00e4mofiltration am INUS\n                    Tagesklinikum, Cham, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Graessler","sequence":"additional","affiliation":[{"name":"Department and Outpatient Department of Medicine III, University\n                    Hospital Carl Gustav Carus, Dresden, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"U.","family":"Julius","sequence":"additional","affiliation":[{"name":"Department and Outpatient Department of Medicine III, University\n                    Hospital Carl Gustav Carus, Dresden, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Tselmin","sequence":"additional","affiliation":[{"name":"Department and Outpatient Department of Medicine III, University\n                    Hospital Carl Gustav Carus, Dresden, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roman N.","family":"Rodionov","sequence":"additional","affiliation":[{"name":"Department and Outpatient Department of Medicine III, University\n                    Hospital Carl Gustav Carus, Dresden, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Barbir","sequence":"additional","affiliation":[{"name":"Royal Brompton Hospital, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Walls","sequence":"additional","affiliation":[{"name":"GENinCode, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Theofilatos","sequence":"additional","affiliation":[{"name":"Kings College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Mayr","sequence":"additional","affiliation":[{"name":"Kings College London, London, UK"},{"name":"Technische Universit\u00e4t Dresden, Dresden, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.R.","family":"Bornstein","sequence":"additional","affiliation":[{"name":"Kings College London, London, UK"},{"name":"Department and Outpatient Department of Medicine III, University\n                    Hospital Carl Gustav Carus, Dresden, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2022,4,12]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.atherosclerosissup.2019.08.038","article-title":"Lipoprotein apheresis in Germany - Still more commonly indicated than\n                    implemented. How can patients in need access therapy?","volume":"40","author":"F Heigl","year":"2019","journal-title":"Atheroscler Suppl"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.atherosclerosissup.2019.08.037","article-title":"Lipoprotein(a) \u2013 Marker for cardiovascular risk and target for\n                    lipoprotein apheresis","volume":"40","author":"R Klingel","year":"2019","journal-title":"Atheroscler Suppl"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s11789-019-00097-1","article-title":"Lipoprotein(a) apheresis in patients with peripheral arterial disease: rationale\n                    and clinical results","volume":"14","author":"N Weiss","year":"2019","journal-title":"Clin Res Cardiol Suppl"},{"key":"ref4","first-page":"7","article-title":"Why some patients undergoing lipoprotein apheresis therapy develop new\n                    cardiovascular events?","author":"U Julius","year":"2020","journal-title":"J Cardiovasc Dev Dis"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1194\/jlr.RA120001132","article-title":"LDL apheresis as an alternate method for plasma LPS purification in healthy\n                    volunteers and dyslipidemic and septic patients","volume":"61","author":"A Dargent","year":"2020","journal-title":"J Lipid Res"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S1567-5688(09)71806-9","article-title":"Acute effects of lipid apheresis on human serum lipidome","volume":"10","author":"S Tselmin","year":"2009","journal-title":"Atheroscler Suppl"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1002\/jca.21413","article-title":"Lipoprotein apheresis reduces circulating galectin-3 in humans","volume":"31","author":"I Eliaz","year":"2016","journal-title":"J Clin Apher"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1111\/j.1744-9987.2006.00332.x","article-title":"LDL-apheresis reduces P-Selectin, CRP and fibrinogen \u2013 possible\n                    important implications for improving atherosclerosis","volume":"10","author":"S Kobayashi","year":"2006","journal-title":"Ther Apher Dial"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.atherosclerosis.2004.01.017","article-title":"Long-term reduction of C-reactive protein concentration by regular LDL\n                    apheresis","volume":"174","author":"C Otto","year":"2004","journal-title":"Atherosclerosis"},{"key":"ref10","first-page":"575","article-title":"Effects of LDL-apheresis-more than reduction of cholesterol?","volume":"132","author":"V Schettler","year":"2007","journal-title":"Dtsch Med Wochenschr"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1111\/1744-9987.12056","article-title":"Proteomic analysis of proteins eliminated by low-density lipoprotein\n                    apheresis","volume":"18","author":"Y Yuasa","year":"2014","journal-title":"Ther Apher Dial"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.atherosclerosis.2009.06.010","article-title":"Efficacy criteria and cholesterol targets for LDL apheresis","volume":"208","author":"G R Thompson","year":"2010","journal-title":"Atherosclerosis"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.ijcard.2021.10.024","article-title":"LDL cholesterol target achievement in heterozygous familial hypercholesterolemia\n                    patients according to 2019 ESC\/EAS lipid guidelines: Implications for\n                    newer lipid-lowering treatments","volume":"345","author":"C V Rizos","year":"2021","journal-title":"Int J Cardiol"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1161\/HYPERTENSIONAHA.117.09242","article-title":"Complement factor B is a determinant of both metabolic and cardiovascular\n                    features of metabolic syndrome","volume":"70","author":"P M Coan","year":"2017","journal-title":"Hypertension"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1007\/s11255-021-02997-2","article-title":"Serum complement factor B is associated with disease activity and progression of\n                    idiopathic membranous nephropathy concomitant with IgA nephropathy","author":"F P Ji","year":"2021","journal-title":"Int Urol Nephrol"},{"key":"ref16","first-page":"177","article-title":"Plasma heparin cofactor II activity correlates with the incidence of in-stent\n                    restenosis after the intervention of arteriosclerosis obliterans in lower\n                    extremity","volume":"40","author":"H Lu","year":"2015","journal-title":"Zhong Nan Da Xue Xue Bao Yi Xue Ban"},{"key":"ref17","first-page":"22","article-title":"Complement factor B mediates ocular angiogenesis through regulating the VEGF\n                    signaling pathway","author":"H Murray","year":"2021","journal-title":"Int J Mol Sci"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.bbrc.2017.11.069","article-title":"Adipose tissue complement factor B promotes adipocyte maturation","volume":"495","author":"H Matsunaga","year":"2018","journal-title":"Biochem Biophys Res Commun"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"17394","DOI":"10.1038\/s41598-021-96995-0","article-title":"The human type 2 diabetes-specific visceral adipose tissue proteome and\n                    transcriptome in obesity","volume":"11","author":"N J Carruthers","year":"2021","journal-title":"Sci Rep"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1038\/s41598-020-79429-1","article-title":"Plasma protein expression profiles, cardiovascular disease, and religious\n                    struggles among South Asians in the MASALA study","volume":"11","author":"L H Ngo","year":"2021","journal-title":"Sci Rep"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1002\/jca.21636","article-title":"Changes in serum afamin and vitamin E levels after selective LDL apheresis","volume":"33","author":"V E Varga","year":"2018","journal-title":"J Clin Apher"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"670425","DOI":"10.3389\/fendo.2021.670425","article-title":"Serum afamin a novel marker of increased hepatic lipid content","volume":"12","author":"T Kurdiova","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1186\/s12933-019-0935-9","article-title":"Predictive and diagnostic biomarkers for gestational diabetes and its associated\n                    metabolic and cardiovascular diseases","volume":"18","author":"A Lorenzo-Almor\u00f3s","year":"2019","journal-title":"Cardiovasc Diabetol"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.2337\/dc17-0201","article-title":"Plasma concentrations of afamin are associated with prevalent and incident type\n                    2 diabetes: a pooled analysis in more than 20,000 individuals","volume":"40","author":"B Kollerits","year":"2017","journal-title":"Diabetes Care"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"e4157","DOI":"10.1210\/clinem\/dgaa558","article-title":"Identification of proteins associated with the early restoration of insulin\n                    sensitivity after biliopancreatic diversion","volume":"105","author":"C Karlsson","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.diabres.2018.02.034","article-title":"Urinary afamin levels are associated with the progression of diabetic\n                    nephropathy","volume":"147","author":"Y Kaburagi","year":"2019","journal-title":"Diabetes Res Clin Pract"},{"key":"ref27","first-page":"146","article-title":"The positive effect of short-term nano-curcumin therapy on insulin resistance\n                    and serum levels of afamin in patients with metabolic syndrome","volume":"11","author":"N Kheiripour","year":"2021","journal-title":"Avicenna J Phytomed"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.gene.2012.02.006","article-title":"Aberrant expression of Fc\u03b3RIIIA (CD16) contributes to the development of\n                    atherosclerosis","volume":"498","author":"Y Huang","year":"2012","journal-title":"Gene"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.atherosclerosis.2004.12.011","article-title":"Fcgamma receptor IIIA polymorphism as a risk-factor for coronary artery\n                    disease","volume":"180","author":"S Gavasso","year":"2005","journal-title":"Atherosclerosis"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.atherosclerosis.2005.10.040","article-title":"Increased soluble FcgammaRIIIa (Mphi) in plasma from patients with coronary\n                    artery diseases","volume":"188","author":"M Masuda","year":"2006","journal-title":"Atherosclerosis"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1089\/gtmb.2018.0248","article-title":"The effect of AMBP SNPs, their haplotypes, and gene-environment interactions on\n                    the risk of atherothrombotic stroke among the Chinese population","volume":"23","author":"H Liu","year":"2019","journal-title":"Genet Test Mol Biomarkers"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1016\/j.ekir.2017.07.007","article-title":"Altered protein composition of subcutaneous adipose tissue in chronic kidney\n                    disease","volume":"2","author":"J Gertow","year":"2017","journal-title":"Kidney Int Rep"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.bbrc.2021.07.046","article-title":"Effects of IGFBP3 knockdown on human endometrial mesenchymal stromal cells\n                    stress-induced senescence","volume":"570","author":"R E Ushakov","year":"2021","journal-title":"Biochem Biophys Res Commun"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"3212","DOI":"10.3390\/jcm9103212","article-title":"PromarkerD predicts renal function decline in\n                    type 2 diabetes in the canagliflozin cardiovascular assessment study\n                    (CANVAS)","volume":"9","author":"K E Peters","year":"2020","journal-title":"J Clin Med"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1016\/j.bbrc.2017.01.042","article-title":"Alpha-2-macroglobulin and heparin cofactor II and the vulnerability of carotid\n                    atherosclerotic plaques: An iTRAQ-based analysis","volume":"483","author":"J Li","year":"2017","journal-title":"Biochem Biophys Res Commun"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.yexmp.2009.09.003","article-title":"Heparin cofactor II in atherosclerotic lesions from the pathobiological\n                    determinants of atherosclerosis in youth (PDAY) study","volume":"87","author":"J C Rau","year":"2009","journal-title":"Exp Mol Pathol"}],"container-title":["Hormone and Metabolic Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-1776-7943.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,11]],"date-time":"2022-05-11T23:25:04Z","timestamp":1652311504000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-1776-7943"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":36,"journal-issue":{"issue":"04","published-online":{"date-parts":[[2022,4,12]]},"published-print":{"date-parts":[[2022,4]]}},"URL":"https:\/\/doi.org\/10.1055\/a-1776-7943","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0018-5043","1439-4286"],"issn-type":[{"value":"0018-5043","type":"print"},{"value":"1439-4286","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4]]}}}